European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
RegulatoryapprovedJASCAYDPositive
AI Analysis
Summary
The European Commission has approved JASCAYD, a novel oral treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This regulatory approval represents a significant milestone bringing a new therapeutic option to the European market.
Outcome Details
European Commission approval for JASCAYD
Importance:8/10
Sentiment:
0.85
European approvalIPFPPForal treatmentregulatory milestone
Read the original article
Published by GlobeNewswire Pharma on July 17, 2026 6:10 AM